PF 02341066 - Crizotinib | PF 2341066

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 1660

CAS [877399-52-5]

MF C21H22Cl2FN5O
MW 450.34

  • Purity: 99%
  • Optical purity: Optically pure
  • Soluble in DMSO

PF 02341066

Description

Potent, selective and ATP-competitive inhibitor of c-Met/HGF receptor and the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), with IC50 values to be 4 and 25 nM for c-Met and ALK respectively. (R)-Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-smal-cell lung cancer with ALK rearrangement.
Notably, (S)-Crizotinib (Axon 2296) was recently found to potently inhibit the MTH1 phosphatase enzyme, whereas the (R) enantiomer is inactive (IC50 values of 72 nM and 1375 nM resp.).

Order
Size Unit Price Stock
10 mg €80.00 In Stock
50 mg €220.00 In Stock
Special Offers
Size Unit Price Stock
2 x 10 mg €120.00 In Stock
2 x 50 mg €320.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...